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ementia has as its central feature impairment in
cognitive function. Clinically, the cognitive deficit will
most often manifest itself as memory problems and most
usually as difficulties in the ability to retain new infor-
mation. However, a number of other areas of cognition
are affected and it is important to realize that memory is
but one of the cognitive skills compromised in dementia.
Dementia is thus prima facie a disorder of cognition and
it is our cognitive facilities that underlie our abilities to
engage successfully in the activities of daily living (ADL).
From this it follows that enhancement to cognitive func-
tion will facilitate performance of these ADL.The assess-
ment and understanding of these impairments are crucial
to any treatment of the disorder.
Behavioral observation today has a very limited role to
play in the assessment of mental ability, as it is now known
that many important aspects of cognitive function are not
readily assessable by this technique. Cognition can only
truly be assessed accurately through the direct use of
objective psychometric tests. However, historically the
diagnosis of dementia has been largely the province of
gerontologists and old-age psychiatrists, who, in the
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often manifests itself as memory problems, a number of other areas of cognition are affected, and memory is but
one of the cognitive skills compromised in dementia. Dementia with Lewy bodies, for example, accounts for 15% to
25% of all dementias and does not have memory deficits as a core feature. Our cognitive facilities underlie our abil-
ities to engage successfully in the activities of daily living (ADL) and it follows that enhancement of cognitive func-
tion will facilitate performance of ADL. The assessment and understanding of these impairments are crucial to any
treatment of the disorder. Unfortunately, the principal instrument used to assess cognitive function in most of the
major clinical trials of Alzheimer’s disease in recent years, the Alzheimer’s Disease Assessment Scale–Cognitive
Subsection (ADAS-COG), primarily assesses aspects of memory, which has resulted in other important cognitive deficits
in dementia being overlooked. Automated cognitive tests are now available that can identify an earlier onset of
improvements in dementia in smaller samples than the ADAS. Regulatory authorities should encourage—or even
require—the use of automated procedures alongside the ADAS in pivotal trials to help determine the relative util-
ity of the instruments in the fairest way possible. Whatever the outcome, this will be of long-term benefit to patients,
carers, drug developers, clinicians, and regulators in this important area. Dialogues Clin Neurosci. 2003;5:77-88.
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absence of widely accepted tasks, relied primarily on their
clinical judgment. Memory deficits are one of the more
obvious aspects of cognitive disorder, both to the patient
and the observer; therefore, the marked anterograde
amnesia seen in Alzheimer’s and other dementias became
the hallmark of the disorders. This legacy remains today
and can be evidenced by inspecting the Diagnostic and
Statistical Manual of Disorders, Fourth Edition (DSM-IV)
guidelines for any of the dementias.1 Nonetheless, as will
emerge in this chapter, memory deficits are only one of
several major aspects of cognitive dysfunction in demen-
tia. Unfortunately, the principal instrument used in most
of the major clinical trials of Alzheimer’s disease (AD) in
recent years, the Alzheimer’s Disease Assessment
Scale–Cognitive Subsection (ADAS-COG), primarily
assesses aspects of memory, which has resulted in other
important cognitive deficits in dementia being overlooked.
As a consequence, the full therapeutic potential of the
treatments studied has not been evaluated.
Assessment of cognitive function
Cognitive functions are those aspects of mental activ-
ity that underpin the quality with which we are able to
conduct ADL. A number of these aspects of mental
activity are subject to change in the efficiency with which
they operate.These include attention, short-term (work-
ing) memory, long-term memory, reasoning, the coordi-
nation of movement, and the planning of tasks. Besides
changes due to diurnal rhythms, a wide range of external
and internal events can affect the operation of these cog-
nitive functions, including anxiety, fatigue, aging, trauma,
disease, psychiatric illness, drugs, hormones, cardiac func-
tion, and of course, dementia.
Cognitive function is assessed by requiring subjects (vol-
unteers or patients) to perform specific tasks. The qual-
ity of measurement depends on how well the perfor-
mance of the tasks can be assessed. This is a very
important issue, as the process of precisely estimating an
individual’s level of cognitive competence is affected by
a number of sources of error variance. Clearly, when
measuring performance, we are hoping to obtain a reli-
able and precise estimate of an individual’s cognitive
competence.There are two principal applications of cog-
nitive function tests in clinical practice and research.The
first is to identify the ability to conduct the tasks in order
to make an assessment of the cognitive capabilities of the
particular individual.An obvious example in the context
of this article would be to determine the presence and,
possibly, degree of dementia. The second is to assess
change in cognitive function, ie, to assess a person more
than once in order to determine whether the quality of
function has altered during the time between the assess-
ments.The latter application is crucial in trials of demen-
tia therapies in which the desire is to determine whether
cognitive function has been affected by the therapy.
Individuals vary widely in the quality of their various
mental skills and simply assessing them after treatment
provides little insight into the nature or extent of any
changes.The key to such work is to assess the abilities of
the individual prior to treatment and then determine the
extent to which these have changed in subsequent
assessments. However, repeating cognitive testing in this
manner places very stringent constraints on the design
and types of tests that can be used.These constraints are
not present in many other fields, for example, the
repeated assessment of biometric measures such as
blood pressure or body weight. With psychometric
assessments, which include cognitive tests, performance
can change with repeated testing for a variety of reasons
that are independent of the study treatment. Examples
of these are as follows.
Selected abbreviations and acronyms
AD Alzheimer’s disease
ADAS-COG Alzheimer’s Disease Assessment Scale—
Cognitive Subsection
ADL activities of daily living
CANTAB Cambridge Neuropsychological Test
Automated Battery
CDR Cognitive Drug Research
CNTB Computerized Neuropsychological Test Battery
CPMP Committee for Proprietary Medicinal Products
DLB dementia with Lewy bodies
EBI economic buying influence
EMEA European Agency for the Evaluation of
Medicinal Products
EWP Efficacy Working Party
HD Huntington’s disease
MCI mild cognitive impairment
MMSE Mini-Mental State Examination
NfG note for guidance
NPI Neuropsychiatric Inventory
SKT Syndrome Kurtz Test
VaD vascular dementia
79
• Learning specific items in memory tests.
• Developing strategies to improve performance.
• Becoming less anxious.
• Improving cognitive skills via training effects.
• Better understanding of the task requirements.
Test developers seek to overcome such effects by devel-
oping parallel forms of the tests, for example, having dif-
ferent sets of items to be learned in memory tests, or
unpredictable sequences of events in tests of attention.
Some forms of tests simply cannot be used, ie, those
involving a single strategy, which, once learned, cannot
be repeated, or those which, like video games, have no
ceiling on practice effects.When sufficient parallel forms
are available, evaluations can be conducted of the num-
ber of familiarization sessions that are required.
Unwarranted test anxiety (some poorly designed tests
can be anxiogenic), full understanding of the task
requirements, and the determination of optimal strate-
gies can, for many tests in current use, be overcome by
two to four repetitions.
Another important control in test design and adminis-
tration is to ensure that changes in performance of the
tasks reflect the quality of the particular aspect of func-
tion under study, and not peripheral changes such as
alterations to visual function.This can often be achieved
by making stimuli large enough that alterations to acu-
ity, for example, will not noticeably affect performance.
As there are a variety of independent cognitive func-
tions that need to be assessed in clinical trials, tests
should ideally be as specific as possible to particular
aspects of cognitive function. Also, it is essential that all
aspects of performance that are important in the execu-
tion of a task be assessed. For example, if the ability to
recognize previously presented items is being measured,
the time taken to make the decisions should be precisely
recorded. Amazingly, this is done in very few memory
tests. This is rather akin to attempting to assess intelli-
gence by requiring volunteers to solve problems, but
either not introducing a time constraint or not measur-
ing how long it takes to solve the problems.
Automating cognitive function testing 
in dementia
The proper automation of cognitive tests is the only way
forward in clinical research. Automating cognitive tests
can help to overcome many of the problems described
in the preceding section, greatly facilitating and stan-
dardizing test administration, as well as enhancing test
sensitivity. Further, the ability to precisely record cogni-
tive decision times in properly computerized tests can
also enable aspects of function to be assessed, such as
attention and the speed of memory, which are simply not
definitively measurable with pencil and paper tasks.
A wide variety of nonautomated tests have been used
in the assessment of dementia. These include the Kew
Test, the Kendrick Test, the Mattis Dementia Rating
Scale, the Folstein Mini-Mental State Examination
(MMSE),2 the Syndrome Kurtz Test (SKT), and the
Alzheimer’s Disease Assessment Scale (ADAS).
However, computerized tests have also been developed,
the three most widely used being the Cambridge
Neuropsychological Test Automated Battery (CANTAB),3
the Computerized Neuropsychological Test Battery
(CNTB),4 and the Cognitive Drug Research (CDR)
Computerized Assessment System.5
An illustration of the superiority of computerized tests
system to nonautomated tests in dementia came from a
trial in which Mohr et al6 contrasted the CDR system
with ADAS-COG, the Mattis Dementia Rating Scale,
the Wechsler Memory Scale, and the MMSE. The pur-
pose of the study was to contrast the relative utility of
the various systems in differentiating patients with
Huntington's disease (HD) and AD from each other, as
well as from a control group. The authors concluded
that the CDR system was able to reliably discriminate
the two types of dementia, whereas the other assess-
ments described above were not. Further, in terms of
the ability of the various tests to accurately classify the
three groups, the computerized tests scored best over-
all, being able, for example, to accurately identify 77%
of the AD patients, compared with the ADAS-COG,
which managed to classify 67% correctly. Another
notable superiority was 86% accuracy in classifying HD
patients with the automated tests, in comparison to 43%
with the ADAS-COG, little better than chance. Mohr et
al concluded that the assessment of cognitive speed pos-
sible with computerization was an important factor in
the superiority of the automated system to the other
tests.6
The International Working Group on Harmonization of
Dementia Drug Guidelines has formally recognized the
importance of automated cognitive testing in dementia
research.7 In a position paper on “objective psychome-
tric tests in clinical trials of dementia drugs,” the group
acknowledged the utility of computerized testing:
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Automated testing can have clear advantages for clinical
trials in this field. The task information is always pre-
sented in a standard fashion; the recording of responses
is done automatically and precisely, without any bias; and
there are no grey areas involving differences of interpre-
tation.These advantages can reduce variability both from
session to session for a patient, and also between differ-
ent national and international sites. Automated proce-
dures have been shown to be more sensitive than the stan-
dard tests that are used extensively in this field.
For a detailed comparison of computerized versus pencil
and paper assessment testing see Wesnes et al.8 Another
important landmark from the position paper was that it
acknowledged that the importance of deficits to attention
and information processing in the cognitive symptoma-
tology of AD and other dementias had been largely over-
looked, and identified these as domains which should in
future be assessed in AD trials.The group also recognized
that the ADAS is not appropriate for mildly impaired or
at-risk populations.
As speed is such a crucial assessment in cognitive testing,
everything possible should be achieved to ensure that it
is assessed as accurately as possible. Software should be
able to resolve reaction times to the nearest millisecond,
which, it should be noted, is not the same as simply giving
a score in milliseconds, but with a resolution of say 50 ms.
Everything should be done to get the response recorded
as quickly as possible, which would, for example, involve
avoiding the patient using the keyboard, as the in-built
software of PCs only samples this once every 30 ms or so.
Also, it should be the patient making the response, not the
tester.The use of touchscreens, while potentially of bene-
fit in some types of test, must be carefully managed. The
very nature of touchscreens requires the subject to move
his/her responding digit to the screen in order to record
response time. This task requirement runs the risk of
introducing significant levels of error. For example,
repeated assessment of this kind can introduce significant
fatigue in elderly subjects.A further essential task require-
ment is to ensure that the starting finger position be con-
sistent both within and between subjects. Some touch-
screen-based tests measure reaction time (ie, the time
taken to release a home key) and movement time (ie, the
time taken to reach a target on the touchscreen).This is a
useful decomposition of performance parameters.
However, it is essential that the home key accurately
records latencies and is of a type and construction that
does not selectively disadvantage specific groups of sub-
jects.
Other important methodological issues are to avoid
stressful feedback when patients make incorrect
responses and to keep the duration of testing to just a few
minutes for each test. Systems that can be administered
by nonspecialists are advantageous as this facilitates their
use in multiple site trials. Tests should ideally measure
core domains of human cognitive function discussed ear-
lier, particularly verbal, pictorial, and spatial memory,
working as well as episodic secondary memory, various
aspects of sustained and focussed attention, and aspects
of planning and executive function. Finally, of course, it is
necessary besides these considerations of utility to have
evidence of the validity, reliability, and sensitivity of the
procedures.
If computerized tests are used in clinical trials, all aspects
of data capture and processing must of course be suffi-
ciently documented to allow audit to ensure they comply
with International Conference on Harmonisation (ICH)
good clinical practice (GCP). If the data from testing is to
be submitted to the Food and Drug Adminstration
(FDA), all systems that are used to capture, process, and
analyze the cognitive data must in addition be fully com-
pliant with FDA 21 Code of Federal Regulations (CFR)
Part 11 and FDA guidance for computerized systems used
in clinical trials. Developing new systems in compliance
with 21 CFR Part 11 and making existing systems com-
pliant are both lengthy and often expensive procedures,
which sadly preclude most academically developed tests
from playing an important role in drug development.
Finally, it must be accepted that cognitive assessment falls
within the current domain of psychology, and that
researchers not formally trained in psychology should not
be in a position to administer and interpret changes from
cognitive tests without the close supervision from a suit-
ably qualified psychologist. This is not a protectionist
approach from a territorial sense of others encroaching
on the discipline of psychology, rather it is in frustration
at the widespread superficial application and question-
able interpretation of psychological test results by
researchers not qualified to conduct or interpret these
tests. Journals should require evidence of the involvement
of psychologists in research before accepting for publica-
tion papers on trials in which cognitive tests have been
utilized. Regulatory authorities should mandate the
requirement that cognitive data from clinical trials be
gathered and interpreted under the supervision of a suit-
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ably qualified psychologist. Providers of cognitive tests
should ensure that they do not sell the tests to researchers
not qualified in psychology or groups without a suitably
qualified psychologist. Such restrictions apply to most
other psychological instruments, such as personality and
aptitude tests, and there is no reason why they should not
be applied to the use of tests in drug development.
The profile of cognitive impairment 
in dementia
The profile of cognitive impairments in dementia has not
traditionally included impairments to attention. This is
evident in the DSM-IV criteria for all of the dementias,1
where attentional deficits are not even considered as pos-
sible symptoms. Further, the scale developed specifically
to assess Alzheimer’s patients, the ADAS, does not con-
tain an assessment for attention.As suggested earlier, this
oversight was probably the result of physicians relying on
their clinical judgment, and thus missing less obvious
deficits. However, deficits to various aspects of attention
in AD have been reported in the literature since 1989,5,9
and interest in these deficits has now become wide-
spread.10-12 Importantly, volunteer trials with drugs that
stimulate or block the cholinergic system have shown
that attention as well as memory can be influenced by the
administration of drugs that directly influence the cholin-
ergic system.13 Further, cholinergic blockade in volunteers
with scopolamine mimics the attentional deficits seen in
AD.14,15 This indicates that the cholinergic system plays an
important role in controlling various aspects of atten-
tional function. In AD cholinergic deficits lead to atten-
tional impairment, which is therefore central to the cog-
nitive pathology of the disorder. All the preceding
evidence would result in the prediction that the anti-
cholinesterases should enhance attention as well as mem-
ory in AD. This is precisely what has occurred in trials
that have assessed attention; improvements to attention
in AD have been seen with the anticholinesterases
tacrine,16,17 velnacrine,18 and galantamine.19
Other major forms of dementia also have impairments
to attention as a core feature of the diseases. In the Mohr
et al6 study cited earlier, the HD patients showed greater
impairments to attention on the CDR tests, whereas they
had smaller deficits to episodic memory. Patients with
vascular dementia (VaD) also have greater attentional
deficits than AD patients,20,21 and show smaller impair-
ments to memory.20 Dementia with Lewy bodies (DLB)
completely breaks the traditional mold in dementia by
having attention deficits identified as a core feature of
the syndrome.22 These patients also have larger atten-
tional deficits than AD patients while, like HD and VaD
patients, they have relatively preserved episodic mem-
ory.21,23 Further, the attentional deficits seen in DLB are
not only quantitatively, but also qualitatively different
from those seen in AD. For example, the variability in
reaction times in a 90-s computerized test of attention,
choice reaction time, can discriminate between the two
types of dementia with a sensitivity of 81% and a speci-
ficity of 92%.21 Importantly, different profiles of atten-
tional impairment can be seen in all the major types of
dementia (VaD,AD, and DLB21), probably reflecting the
differing etiologies of the conditions.Thus, DLB can also
be differentiated from VaD with a sensitivity of 81% and
a specificity of 82%, while AD can be differentiated from
VaD with a sensitivity of 64% and a specificity of 77%.21
Attentional impairments have also been seen in first time
diagnosed unmedicated Parkinson’s disease patients,24
Parkinson’s dementia,25 and elderly stroke patients actu-
ally free from dementia.26
Besides marked deficits to attention,27 demented patients
show marked reductions in the speed with which they
can recognize previously presented information (words,
pictures, faces5,6,23). These deficits are also characteristic
of mild cognitive impairment (MCI)28 and add a further
dimension to our knowledge of the cognitive deficit pro-
files in the dementias that have gone undetected by
nonautomated assessments like the ADAS. The behav-
ioral impact of delays in time to retrieve information
from working and secondary memory is manifest in a
variety of behavioral situations. For example, in social sit-
uations, in which not only is the patient clearly forgetful,
but even when items are retrieved or objects (or people)
recognized, the increased time lag makes social interac-
tions more stressed and unsatisfactory. Other examples
are patients not remembering the name of someone until
after they have passed by in the street, or remembering
to do something too late or in the wrong context.
Historical perspectives on cognitive 
assessment of dementia
Alzheimer’s disease
Since the registration of the anticholinesterase, tacrine,
for the symptomatic treatment of AD in the late 1980s,
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the cognitive outcome measure most frequently used in
clinical drug trials for new dementia drugs has been the
cognitive subscale of the ADAS (ADAS-COG).
However, the ADAS-COG features some well-recog-
nized deficiencies,29-31 which, as the following examples
will illustrate, have been recognized by the International
Working Group on Dementia Drug Guidelines7:
A generally acknowledged limitation of the ADAS-COG
is that it lacks a subset for attention. […] Given the pre-
viously noted importance of assessing attention and pro-
cessing speed in patients with AD, computerized tests can
provide optimal procedures for assessing changes in these
functions. […] If clear advantages of computerized pro-
cedures are demonstrated, such procedures might super-
sede existing methods.
This situation has led drug developers to seek more sen-
sitive cognitive outcome measures. Regulators, particu-
larly the Efficacy Working Party of the European
Medicines Approval Agency, have also opened the pos-
sibility of using other, non–ADAS-COG measures.
Clinical trials of drugs developed for the amelioration of
dementia and especially AD tend to require large num-
bers of study participants and are typically of quite long
duration. Regulators both in Europe and the USA have
specified the collection of extensive safety data in sup-
port of an application for a marketing license. For exam-
ple, Leber has specified that a minimum level of safety
information is to be based on data for N=1000 study par-
ticipants collected over a 6-month period.32 Furthermore,
a subset of at least N=300 participants must be further
studied for 1 year or more. However, with respect to
showing evidence of efficacy, a combination of modest
degrees of drug efficacy and the use of relatively insen-
sitive instruments has meant that typically hundreds of
study participants are required for trials lasting at least
6 months and often considerably longer. Added to this
situation is the practical and ethical difficulty of recruit-
ing patients for the placebo arm of these trials. These
demanding requirements have made large, multicenter,
international trials a necessity.
The routine inclusion of the notoriously unreliable clin-
icians' impression scales is seen as tacit acceptance of
the failure of current cognitive outcome measures to
capture the clinically significant improvements seen in
patients. It therefore seems clear that pretenders to the
ADAS-COG’s crown will benefit from being demon-
strably robust proxy measures of everyday cognitive
improvement. Intuitively, it seems reasonable to sup-
pose that enhancements in cognition seen in laboratory-
based assessments will be reflected as improvements in
day-to-day activities reliant upon reasonable degrees of
cognitive competence. One method for validating labo-
ratory-based methods would be to correlate them
against concurrently run ADL and quality of life ques-
tionnaires. The result of such a validation project may
well yield cognitive outcome measures that are power-
ful and accurate proxy measures of clinically significant
drug enhancements. This validation has the potential to
make clinicians’ rating scales redundant as a means of
capturing the positive effects of pharmaceutical inter-
ventions.
Dementia with Lewy bodies
DLB accounts for 15% to 25% of all dementia.33 As
described earlier, DLB is a newly diagnosed form of
dementia for which consensus criteria have emerged in
recent years. Here are the consensus criteria for a diag-
nosis of probable DLB34:
• The central feature required for a diagnosis of DLB is
progressive cognitive decline of sufficient magnitude
to interfere with normal social or occupational func-
tion. Prominent of persistent memory impairment may
not necessarily occur in the early stages, but is usually
evident with progression. Deficits on tests of attention
and frontosubcortical skills and visuospatial ability
may be especially prominent.
Plus two of the following essential features:
• Fluctuating cognition with pronounced variations in
attention and arousal.
• Recurrent visual hallucinations, typically well-formed
and detailed.
• Spontaneous motor features of Parkinsonism.
It is evident from the criteria that attentional deficits
assessed by tests are a key part of the diagnosis, and that
memory deficits may not be apparent in the early stages.
This makes it clear that the ADAS-COG would not be a
suitable primary outcome measure in a therapeutic trial
of DLB as it does not assess attention or frontosubcorti-
cal skills and visuospatial ability. Thus, in the first ran-
domized, placebo-controlled, double-blind trial of an
anticholinesterase in DLB,33 the two primary outcome
measures were a compound speed score derived from
the CDR cognitive assessment system and a DLB-typi-
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cal summary score from the Neuropsychiatric Inventory
(NPI). This was a prospective, multicenter, randomized,
double-blind, 20-week, placebo-controlled study con-
ducted in the UK, Spain, and Italy.Testing was conducted
prior to dosing, at weeks 12 and 20 after the commence-
ment of dosing, and again 3 weeks after dosing was
stopped. Analysis of the data from the 92 patients who
completed the study identified a significant pattern of
benefits of rivastigmine over placebo on the two main
outcome criteria. Benefits on the CDR system measures
were seen on tests of attention, working memory, and
episodic secondary memory. For example, on the speed
score from the computerized tests, patients given placebo
showed significant deterioration from predosing at weeks
12 and 20, whereas patients on rivastigmine performed
significantly above their predosing levels. Some quotes
from the parts of a paper33 prepared by the physicians
indicate the growing acceptance of the clinical relevance
of measuring the speed of cognitive function:
Since behavioral slowing and severely impaired attentional
function are key features of Lewy-body dementia, we used
the sum of the latencies for the computerized cognitive
assessment tests (speed score) as the second primary effi-
cacy measure. […] Improvements in psychiatric and
behavioral features were mirrored by changes in cognitive
performance. […] The clinical relevance of these improve-
ments in attention was captured in caregiver reports of
patients, describing them as more alert and switched on,
and emphasized by reduced apathy scores on NPI.
A commentary in the Lancet35 on this trial also revealed
the widening acceptance of computerized tests in
dementia research:
The use of reaction times as a second primary outcome
measure is another novel feature of this trial. […]
Neuropsychological functions other than those evaluated
with the ADAS-COG […] are also relevant to the treat-
ment of patients with dementia. […] McKeith and
coworkers show that other features, such as psychologi-
cal symptoms and reaction times, can be meaningful out-
come measures in dementia drug trials.
These effects seen in this trial were also large in magni-
tude: at week 12 a factor score, power of attention,
declined by 19% on placebo compared with an improve-
ment of 23% on rivastigmine.36 From the above, it seems
clear that there is little relevance for the ADAS for
DLB, except possibly as a secondary measure to com-
pare findings to previous trials with AD. Attention is a
core feature of the disease, as is behavioral and mental
slowing, which means that assessing attention, speed of
access to memory, as well as overall memory perfor-
mance with a computerized system is clearly optimal.
Another contribution to the estimation of clinical rele-
vance in this trial was that the system used has a large nor-
mative database.This has allowed the clinical relevance of
these data to be assessed. In this trial, rivastigmine reduced
the DLB deficit on the power of attention factor (the dif-
ference between the DLB patients and age-matched con-
trols) by 33%.36 In other words, the attentional impair-
ments in the patients were pushed one third of the way
back towards being normal, a large effect size and one for
which the clinical relevance is clearly apparent.This should
be contrasted with the ADAS, which does not have a data-
base of scores for normals.The only way of assessing the
clinical relevance of effects on ADAS-COG is to use the
number of points moved in order to estimate how long
treatment may prevent the patient from becoming insti-
tutionalized.This is obviously important, and the comput-
erized system also has similar longitudinal data and can
thus make this assessment; but describing treatment
response in terms of the degree to which the patient has
been “normalized” is an extremely valuable extra piece of
information that has far more intuitive appeal.
This trial confirmed that computerized cognitive tests
can be suitable and effective as primary outcome vari-
ables in dementia trials. More importantly for DLB, it
illustrated that automated tests that incorporate sensi-
tive measures of attention and other cognitive skills not
assessed by the ADAS are more suitable primary out-
come measures. It is clear from this important trial that
for DLB, the ADAS does not have a role as a primary
outcome variable in pivotal trials, though it should be
included as a secondary measure to enable comparisons
to be made to the effects of other treatments in AD.
Regulatory requirements for 
dementia drug trials
The Efficacy Working Party (EWP) of the European
Agency for the Evaluation of Medicinal Products
(EMEA) has provided reasonably specific guidelines for
the use of cognitive testing in clinical drug trials of com-
pounds for use in dementia.
The “Note for Guidance” (NfG) document published by
the EWP states that “improvement of symptoms should
be assessed in the following three domains”:
• Cognition.
• ADL.
• Overall clinical response.
Little guidance is given with respect to the specific cog-
nitive tests that should be administered and the authors
of the NfG acknowledge that:
Whilst a large number of methods for evaluation of cog-
nitive functions and behavioral changes have been sug-
gested, none has convincingly emerged as the reference
technique. […] Hence the choice of assessment tools
should remain open, provided that the rationale for their
use is presented, and justified.
This statement provides for the possibility of using cog-
nitive outcome variables other than the ADAS-COG.
Thus, it is possible to consider adopting cognitive tests
that have the propensity to show efficacy in fewer
patients and in trials that are briefer than the typical
ADAS-COG trial. Such an opportunity would be wel-
comed in early phase 2 trials, where proof of principle
and/or optimal dose ranges are sought. Patient numbers
in the previously mentioned trials with the CDR system
were modest (tacrine, n=32; velnacrine, n=35; galanta-
mine, n=30). The DLB trial mentioned in the previous
section involved 92 patients. In a further bridging trial
with S12024 in AD, significant cognitive effects with
computerized tests were seen in 53 AD patients.37 Such
tests thus have much utility in phase 2 trials, and it is pos-
sible to use them even earlier in the development
process. In one trial, acute effects of a potential antide-
mentia compound were seen by administering comput-
erized tests prior to dosing and 15, 40, and 240 min after-
wards in 12 Alzheimer’s patients.38 The latter trial shows
that demented patients can be tested in phase 1 condi-
tions, and opens the possibility for cognitive bridging tri-
als between phases 1 and 2.
It might also be possible to persuade European regula-
tors to grant marketing approval on the basis of results
obtained using non–ADAS-COG outcome measures.
Clearly, this course of action would benefit from discus-
sion with both the cognitive test provider and the regu-
lators themselves. Experience suggests that a relatively
quick and accessibly priced method of soliciting a reg-
ulatory opinion is to approach a national agency, such as
the UK’s Medicines Control Agency, which has proven
helpful during recent enquiries.
Further details on cognitive testing requirements for
dementia drug trials are given in Section 2.2.1 of the
EWP NfG under the heading “Objective cognitive tests”:
Objective tests of cognitive function must be included in
the psychometric assessment; such tests or batteries of tests
must cover more than just memory, as impairments in
domains other than memory are mandatory for the diag-
nosis of AD and the assessment of its severity. Within the
domain of memory, several aspects should be assessed.
These are learning of new material, remote as well as
recent memory, and recall and recognition memory for
various modalities (including verbal and visuospatial).
Other cognitive domains such as language, constructional
ability, attention/concentration and psychomotor speed
should be assessed as well.
Thus, the NfG provides for the assessment of a signifi-
cant number of different cognitive domains, including
domains not tested by the ADAS-COG, such as psy-
chomotor speed and attention.This reflects the previous
recommendations of the International Working Group
on Dementia Drug Guidelines cited earlier.7 However,
no specific guidance is given regarding which particular
tests should be used in the cognitive assessment. Instead
the authors state that:
The Alzheimer’s Disease Assessment Scale (ADAS) cog-
nitive subscale, dealing with memory, language, con-
struction and praxis, orientation, is widely used. However,
this remains an open research field.
This appears to underline the EWP’s willingness to con-
sider tests other than the ADAS-COG.
Efficacy measurement for trials 
conducted in the USA
The ADAS-COG has become the “gold” standard for
dementia drug trials in the USA, in spite of its acknowl-
edged deficiencies.6 An attempt has been made to rem-
edy the absence of tests of attention from the original
version by the inclusion of two additional nonautomated
tests, bringing the total number of subtests to 13. Given
the status of the ADAS-COG and its continued appar-
ent popularity, the inclusion of this assessment in pivotal
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phase 3 trials of dementia drugs is highly recommended.
It should also be included in larger phase 2 trials, though
not necessarily as the primary outcome. Here, other
more sensitive procedures or tests that cover major
domains of function not covered by the ADAS-COG
could be considered as primary outcomes, as the purpose
of phase 2 trials is to identify optimal doses and dosing
strategies, and also of course proof of concept.
In spite of a perception that ADAS-COG is the only
acceptable outcome measure for use in AD clinical drug
trials, an influential guidance paper published by Leber
during his time with the FDA did not mandate the use
of the ADAS-COG.32
The requirement for coprimary efficacy
Given that dementia is prima facie a disorder of cogni-
tion, it at first seems entirely reasonable to consider
granting marketing approval to drugs that occasion cog-
nitive improvement. However, an important considera-
tion for regulators is the clinical relevance of the
observed cognitive changes. Traditionally, a four-point
ADAS-COG advantage of drug over placebo has been
seen as sufficient evidence of efficacy for regulators to
issue marketing approval. However, recent reviews of
the efficacy of licensed drugs have cast considerable
doubt on the validity of this assumption. For example, in
their 2001 review of dementia drugs, the UK’s National
Institute for Clinical Excellence39 stated that:
It is not clear the extent to which cognitive measures such
as ADAS-COG or MMSE are accompanied by real-life
functional changes that are meaningful to patients and
their carers.
This perspective begins to explain why regulators
require evidence of positive drug effects on either clini-
cian-rated impression of change scales or ADL scales.
Intuitively, it seems reasonable to suppose that enhance-
ments in cognition are likely to be accompanied by
improvements in day-to-day functioning. However, data
in support of this proposition are sparse and the concern
remains that cognitive changes reported using scales
such as the ADAS-COG may not be accompanied by
clinically relevant functional improvements. Clear evi-
dence that cognitive enhancement reliably accompanied
functional improvement might allow us to reduce the
role the clinician’s rating and/or ADL scale assessments.
Evidence from one computerized system is available in
a large trial with data available for 744 AD patients.
Here the Instrumental Activities of Daily Living scale
was administered predosing, together with the comput-
erized cognitive tests. There were highly significant cor-
relations between the ADL scale and the three major
factor scores from the computerized system (r=0.43 for
power of attention, r=0.39 for speed of memory, and
r=0.48 for quality of memory; all P<0.0001). These cor-
relations, while not large in magnitude, clearly identify a
direct relationship between these cognitive assessments
and how well the patients were judged to cope with
everyday activities. In previous work with the same sys-
tem, correlations of up to 0.79 were seen on individual
task measures and the Stockton Geriatric Rating Scale,
a scale completed by ward staff concerning the abilities
of institutionalized geriatric patients to conduct ADL.5
As more data of this kind accumulate so will the accep-
tance grow that changes in tests of cognitive function
have clinical significance for everyday behavior.
Overall conclusions and recommendations
• The traditional dementias, AD and VaD, must be
acknowledged to be far more than simply disorders of
memory. Trials that evaluate the effectiveness of
potential therapies need additionally to include sensi-
tive assessments of the other aspects of dysfunction,
such as attention.
• DLB accounts for between 15% and 25% of all demen-
tias, and does not have memory deficits as a core feature
of the disease.Trials to assess the efficacy of novel treat-
ments for DLB should therefore use cognitive test sys-
tems that address the major impairments of disorder, and
attentional assessments are particularly relevant here.
• Cognitive tests should only be administered under the
direct supervision of individuals suitably trained in
psychology, and proof of such supervision should be a
regulatory requirement.
• Automated cognitive tests are available and can iden-
tify an earlier onset of improvements in dementia in
smaller sample sizes than the ADAS. Such tests should
thus be used in bridging trials between phases 1 and 2,
and also in phase 1 trials to enable smaller and shorter
trials to be conducted for proof of concept to be iden-
tified; as well as for optimal doses and dosing regimen
to be established. However, automated tests will need
to satisfy the stringent ICH GCP and FDA require-
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ments before they can be used in such work.
• More work needs to be conducted to establish the
everyday relevance of tests of cognitive function. Once
this is established, the dependence on insensitive daily
living and functional ability scales will be reduced and
the outcomes in clinical trials will be more appropriate.
• The ADAS-COG is the current gold standard for piv-
otal trials in AD. This situation leads to a number of
major difficulties due to the widely acknowledged inad-
equacies of the scale. The situation is not dissimilar to
that of depression, where the Hamilton Depression
Scale has become the “regulatory gold standard”
despite its widely recognized numerous shortcomings.
The development of antidementia drugs is, however, in
its infancy and there is still time to prevent this field
ending up in the same unsatisfactory situation as exists
in antidepressant development. To achieve this, regu-
latory authorities must encourage or even require the
use of other automated procedures alongside the
ADAS in pivotal trials.This will help determine the rel-
ative utility of the instruments in the fairest way possi-
ble. Either such work will confirm the ADAS as the
optimal tool in the field, or other more suitable tools
will be identified. Either outcome will be to the long-
term benefit of patients, carers, drug developers, clini-
cians, and regulators in this important area. ❏
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La evaluación de la función cognitiva en las
demencias: consideraciones metodológicas y
para las agencias reguladoras
El deterioro de la función cognitiva es la caracte-
rística central de la demencia. Aunque clínicamente
el déficit cognitivo se manifiesta, la mayoría de las
veces, como problema de memoria, hay un número
de otras áreas de la cognición afectadas y la memo-
ria es sólo una de las herramientas cognitivas com-
prometidas en la demencia. La demencia con cuer-
pos de Lewy, por ejemplo, da cuenta del 15% a
25% de todas las demencias y no tiene déficits de
memoria como característica central. Nuestras des-
trezas cognitivas subyacen a nuestras capacidades
para realizar con éxito las actividades de la vida
diaria (AVD) y al continuar con la estimulación de
la función cognitiva se facilitará la ejecución de las
AVD. La evaluación y comprensión de estos dete-
rioros son cruciales para cualquier tratamiento de
este trastorno. Lamentablemente, el principal ins-
trumento utilizado para evaluar la función cogni-
tiva en la mayoría de los ensayos clínicos más
importantes en la Enfermedad de Alzheimer en los
años recientes, la subsección cognitiva de la Escala
de Evaluación de la Enfermedad de Alzheimer
(ADAS-Cog), evalúa primariamente aspectos de
memoria, lo que ha significado que se hayan des-
cuidado otros déficits cognitivos en la demencia.
Actualmente se dispone de pruebas cognitivas
automatizadas, las cuales pueden identificar un ini-
cio más precoz del deterioro en la demencia, en
muestras más pequeñas que para la ADAS. Las
autoridades reguladoras deben favorecer- o aun
requerir- el empleo de procedimientos automati-
zados junto con la ADAS en los ensayos funda-
mentales, para ayudar a determinar la utilidad
relativa de los instrumentos de la forma más ade-
cuada posible. Cualquiera que sea la evolución en
esta área importante, se traducirá en un beneficio
a largo plazo para los pacientes, los cuidadores, los
investigadores de fármacos, los clínicos y las agen-
cias reguladoras.
Évaluation de la fonction cognitive dans les
démences : considérations méthodologiques
et régulatrices
L’altération de la fonction cognitive est l’élément
central de la démence. Bien que, cliniquement, le
déficit cognitif se manifeste le plus souvent par des
problèmes de mémoire, un certain nombre
d’autres domaines de la cognition sont atteints et
la mémoire n’est qu’une des aptitudes lésées lors
de la démence. La démence avec corps de Lewy,
par exemple, compte pour 15 % à 25 % de toutes
les démences et les déficits de la mémoire n’en
sont pas la caractéristique principale. Nos structures
cognitives sous-tendent nos capacités à réaliser
avec succès les tâches quotidiennes et il s’ensuit
que la stimulation de la fonction cognitive facili-
tera l’exécution de ces tâches. L’évaluation et la
compréhension de ces détériorations sont fonda-
mentales quel que soit le traitement du trouble.
Malheureusement, l’outil principal utilisé pendant
les dernières années pour évaluer la fonction
cognitive dans la plupart des essais cliniques de la
maladie d’Alzheimer, l’ADAS-COG (Alzheimer’s
Disease Assessment Scale-Cognitive Subsection),
évalue surtout les aspects de la mémoire, ce qui a
conduit à négliger d’autres déficits cognitifs impor-
tants de la démence. Des tests automatisés cogni-
tifs sont maintenant disponibles et ils peuvent
déceler un début plus précoce des améliorations
lors de la démence avec de plus petits échantillons
que pour l’ADAS. Les autorités réglementaires
devraient encourager, ou même exiger, l’utilisation
de procédures automatisées à côté de l’ADAS dans
des essais pivots pour permettre de déterminer
l’utilité relative des outils de la façon la plus juste.
Quels que soient les résultats, cela apportera un
bénéfice à long terme pour les patients, le person-
nel soignant, l’industrie pharmaceutique, les clini-
ciens et les instances réglementaires dans cet
important domaine.
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